Drug Profile
Interferon beta-1a - Biopartners GmbH/Rentschler
Alternative Names: Biferonex; HSA-free IFN β-1a; Human serum albumin-free interferon betaLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Rentschler
- Developer Biopartners GmbH
- Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 30 May 2009 BioPartners withdraws the centralised marketing application for interferon beta-1a for Multiple sclerosis in European Union
- 19 Feb 2009 The CHMP has issued a negative opinion regarding approval of interferon beta-1a for treatment of Multiple sclerosis in European Union
- 31 Jul 2007 Preregistration for Multiple sclerosis in European Union (Parenteral)